Please log in to view this page
Username
Password
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
